Evaluation of the JAK2V617F mutational burden in patients with philadelphia chromosome negative myeloproliferative neoplasms: A single-center experience

1Barbui T, Thiele J, Gisslinger H, Kvasnicka HM, Vannucchi AM, Guglielmelli P, et al. The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. Blood Cancer J. 2018; 8(2): 15-25. Barbui T Thiele J Gisslinger H Kvasnicka HM Vannucchi AM Guglielmelli P The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion Blood Cancer J 2018 82 15 2510.1038/s41408-018-0054-y580738429426921Search in Google Scholar

2Vannucchi AM, Harrison CN. Emerging treatment for classical myeloproliferative neoplasms. Blood. 2017; 129(6): 693-703. Vannucchi AM Harrison CN Emerging treatment for classical myeloproliferative neoplasms Blood 2017 1296 693 70310.1182/blood-2016-10-69596528028027Search in Google Scholar

3Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005; 352(17): 1779-1790. Kralovics R Passamonti F Buser AS Teo SS Tiedt R Passweg JR A gain-of-function mutation of JAK2 in myeloproliferative disorders N Engl J Med 2005 35217 1779 179010.1056/NEJMoa05111315858187Search in Google Scholar

4Singdong R, Siriboonpiputtana T, Chareonsiri-suthigul T, Kongruang A, Limsuwanachot N, Sirirat T, et al. Characterisation and prognosis significance of JAK2 (V617F), MPL and CALR mutations in Philadelphia negative myeloproliferative neoplasms. Asian Pac J Cancer Prev. 2016; 17(10): 4647-4653. Singdong R Siriboonpiputtana T Chareonsiri-suthigul T Kongruang A Limsuwanachot N Sirirat T Characterisation and prognosis significance of JAK2 (V617F), MPL and CALR mutations in Philadelphia negative myeloproliferative neoplasms Asian Pac J Cancer Prev 2016 1710 4647 4653Search in Google Scholar

5Alshemmari SH, Rajaan R, Ameen R, Al-Drees MA, Almosailleakh MR. JAK2V617F allele burden in patients with myeloproliferative neoplasms. Ann Hematol. 2014; 93(5): 791-796. Alshemmari SH Rajaan R Ameen R Al-Drees MA Almosailleakh MR JAK2V617F allele burden in patients with myeloproliferative neoplasms Ann Hematol 2014 935 791 79610.1007/s00277-013-1988-624362471Search in Google Scholar

6Perricone M, Polverelli N, Martinelli G, Catani L, Ottaviani E, Zuffa E, et al. The relevance of a low JAK2 V617F allele burden in clinical practice: A monocentric study. Oncotarget. 2017; 8(23): 37239-37249. Perricone M Polverelli N Martinelli G Catani L Ottaviani E Zuffa E The relevance of a low JAK2 V617F allele burden in clinical practice: A monocentric study Oncotarget 2017 823 37239 3724910.18632/oncotarget.16744551490628422729Search in Google Scholar

7Ha, JS, Kim YK, Jung SI, Jung HR, Chung, IS. Correlations between Janus Kinase 2V617F allele burdens and clinicohematologic parameters in myeloproliferative neoplasms. Ann Lab Med. 2012; 32(6): 385-391. Ha JS Kim YK Jung SI Jung HR Chung IS Correlations between Janus Kinase 2V617F allele burdens and clinicohematologic parameters in myeloproliferative neoplasms Ann Lab Med 2012 326 385 39110.3343/alm.2012.32.6.385348693123130336Search in Google Scholar

8Jovanovic JV, Ivey A, Vannucchi AM, Lippert E, Oppliger Leibundgut E, et al. Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: A joint European LeukemiaNet MPN&MPNr-EuroNet (COST action BM0902) study. Leukemia. 2013; 27(10): 2032-2039. Jovanovic JV Ivey A Vannucchi AM Lippert E Oppliger LeibundgutE Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: A joint European LeukemiaNet MPN&MPNr-EuroNet (COST action BM0902) study Leukemia 2013 2710 2032 203910.1038/leu.2013.219380625023860450Search in Google Scholar

9Malysz J, Crisan D. Correlation of JAK2 V617F mutant allele quantification with clinical presentation and type of chronic myeloproliferative neoplasm. Ann Clin Lab Sci. 2009; 39(4): 345-350. Malysz J Crisan D Correlation of JAK2 V617F mutant allele quantification with clinical presentation and type of chronic myeloproliferative neoplasm Ann Clin Lab Sci 2009 394 345 350Search in Google Scholar

10Antonioli E, Guglielmelli P, Poli G, Bogani C, Pancrazzi A, Longo G, et al. Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia. Haematologica. 2008; 93(1): 41-48. Antonioli E Guglielmelli P Poli G Bogani C Pancrazzi A Longo G Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia Haematologica 2008 931 41 4810.3324/haematol.1165318166784Search in Google Scholar

11Silver RT, Vandris K, Wang YL, Adriano F, Jones AV, Christos PJ, et al. JAK2V617F allele burden in polycythemia vera correlates with grade of myelofibrosis, but is not substantially affected by therapy. Leukemia Res. 2011; 35(2): 177-182. Silver RT Vandris K Wang YL Adriano F Jones AV Christos PJ JAK2V617F allele burden in polycythemia vera correlates with grade of myelofibrosis, but is not substantially affected by therapy Leukemia Res 2011 352 177 18210.1016/j.leukres.2010.06.017362609120650526Search in Google Scholar